Product image of Zegomib (Bortezomib) supplied by GNH India

Zegomib

Active Ingredient:
Bortezomib
Origin:
EU

Zegomib (Bortezomib)

Zegomib (Bortezomib) is an antineoplastic agent administered intravenously for cancer treatment. This prescription medication targets rapidly dividing cells to support therapy protocols. It is used in select oncology settings under medical supervision. Short-term storage guidance may apply for stability.

Manufacturer / TM Owner

Egis Pharmaceuticals Plc

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

  • Zegomib is used in oncology to manage certain types of cancer by interfering with cell growth processes. It is prescribed for conditions where targeted therapy is indicated, such as multiple myeloma or mantle cell lymphoma. Patients often receive it as part of a broader treatment plan. The drug’s mechanism supports disease control in specific clinical scenarios.

Side Effects

  • Zegomib may cause temporary changes in blood cell counts, leading to increased infection risk or fatigue. Gastrointestinal effects like nausea or diarrhea are commonly reported during therapy. Some patients experience peripheral neuropathy, which can affect sensation in hands or feet. These effects vary by individual and treatment duration.

Precautions & Warnings

  • Zegomib requires careful handling due to its effects on rapidly dividing cells. It should be administered by healthcare professionals in a controlled setting. Patients must report signs of infection, bleeding, or unusual symptoms promptly. Hydration and monitoring are essential during treatment cycles.

Avoid Interactions

  • Zegomib may interact with medications that affect liver enzymes, such as CYP inhibitors or inducers. Combining it with other drugs that impact blood cell counts could increase side effects. Alcohol use may exacerbate certain side effects like dizziness or nausea. Always disclose all medications to your healthcare provider.

Frequently Asked Questions

Zegomib is used to treat certain cancers, including multiple myeloma and mantle cell lymphoma, by slowing or stopping cancer cell growth.

Zegomib is given as an intravenous injection by a healthcare professional in a clinical setting.

Common side effects include fatigue, nausea, diarrhea, and changes in blood cell counts.

Zegomib may interact with other drugs; consult your doctor before combining it with any medications or supplements.

Zegomib is not recommended during pregnancy due to potential risks; discuss alternatives with your healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Bortezomib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT